

## Blood and bone marrow cancers overview


NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest version of this pathway see:

<http://pathways.nice.org.uk/pathways/blood-and-bone-marrow-cancers>

Pathway last updated: 07 November 2017

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.



## 1 Person with a blood or bone marrow cancer

No additional information

## 2 Hodgkin lymphoma

### Brentuximab vedotin

The following recommendations are from NICE technology appraisal guidance on [brentuximab vedotin for treating CD30-positive Hodgkin lymphoma](#).

Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:

- they have relapsed or refractory disease after autologous stem cell transplant and
- the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.

Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:

- they have relapsed or refractory disease after at least 2 previous therapies and
- they cannot have autologous stem cell transplant or multi-agent chemotherapy and
- the conditions of the [managed access agreement](#) are followed.

These recommendations are not intended to affect treatment with brentuximab vedotin that was started in the NHS before this guidance was published. Adults having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

NICE has written information for the public explaining its guidance on [brentuximab vedotin](#).

### Nivolumab

The following recommendation is from NICE technology appraisal guidance on [nivolumab for treating relapsed or refractory classical Hodgkin lymphoma](#).

Nivolumab is recommended, within its marketing authorisation, as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin, when the company provides nivolumab in line with the commercial access agreement with NHS England.

NICE has written information for the public explaining its guidance on [nivolumab](#).

### 3 Leukaemia

[See Blood and bone marrow cancers / Leukaemia](#)

### 4 See what NICE says on myeloma

[See Myeloma](#)

### 5 See what NICE says on non-Hodgkin's lymphoma

[See Non-Hodgkin's lymphoma](#)

### 6 Polycythaemia vera

#### Ruxolitinib

The appraisal of [ruxolitinib for treating polycythaemia vera](#) was terminated because no evidence submission was received from Novartis Pharmaceuticals for the technology. Therefore NICE is **unable to make a recommendation** about the use in the NHS of ruxolitinib for treating polycythaemia vera.

### 7 See what NICE says on medicines optimisation

[See Medicines optimisation](#)

### 8 Service organisation

[See Blood and bone marrow cancers / Service organisation for blood and bone marrow cancers](#)

---

**9 See what NICE says on patient experience**

[See Patient experience in adult NHS services](#)

## SIHMDS

specialist integrated haematological malignancy diagnostic services

## WHO

World Health Organization

## Sources

[Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma \(2017\) NICE technology appraisal guidance 462](#)

[Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma \(2017\) NICE technology appraisal guidance 446](#)

[Ruxolitinib for treating polycythaemia vera \(terminated appraisal\) \(2015\) NICE technology appraisal 356](#)

## Your responsibility

The guidance in this pathway represents the view of NICE, which was arrived at after careful consideration of the evidence available. Those working in the NHS, local authorities, the wider public, voluntary and community sectors and the private sector should take it into account when carrying out their professional, managerial or voluntary duties. Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

## Contact NICE

National Institute for Health and Care Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BT

[www.nice.org.uk](http://www.nice.org.uk)

[nice@nice.org.uk](mailto:nice@nice.org.uk)

0845 003 7781